Content about Channelopathy

January 9, 2014

Forest Labs will buy privately owned drug maker Aptalis for $2.9 billion, Forest said Thursday.

NEW YORK — Forest Labs will buy privately owned drug maker Aptalis for $2.9 billion, Forest said Thursday.

Aptalis specializes in making drugs for gastrointestinal disorders and cystic fibrosis, with sales of $688 million in fiscal year 2013. More than 60% of its sales come from the ulcer treatment Carafate (sucralfate), the inflammatory bowel disease treatment Canasa (melamine) and the cystic fibrosis drug Zenpep (pancrelipase).

November 22, 2013

Cornerstone Therapeutics has added specialty pharmacy Diplomat to its limited-distribution network for a newly approved treatment for cystic fibrosis, Diplomat said Friday.

FLINT, Mich. — Cornerstone Therapeutics has added specialty pharmacy Diplomat to its limited-distribution network for a newly approved treatment for cystic fibrosis, Diplomat said Friday.

Diplomat will distribute Bethkis (tobramycin inhalation solution), which received Food and Drug Administration approval in October for treating chronic bacterial lung infections caused by P. aeruginosa in cystic fibrosis patients.

March 25, 2013

The Food and Drug Administration has approved a treatment for managing a type of bacterial infection in patients with cystic fibrosis.

EAST HANOVER, N.J. — The Food and Drug Administration has approved a treatment for managing a type of bacterial infection in patients with cystic fibrosis.

Swiss drug maker Novartis announced the approval of Tobi Podhaler (tobramycin inhalation powder) for managing cystic fibrosis patients with Pseudomonas aeruginosa, or Pa bacteria, in the lungs.

December 6, 2012

The Food and Drug Administration has given special designation to a treatment made by Biodel for patients with congenital hyperinsulinism, a rare disorder that affects children.

DANBURY, Conn. — The Food and Drug Administration has given special designation to a treatment made by Biodel for patients with congenital hyperinsulinism, a rare disorder that affects children.

Biodel announced that it had received orphan drug designation for glucagon to prevent hypoglycemia, or abnormally low blood sugar, in patients with CHI.

November 19, 2012

The drug-discovery division of the Cystic Fibrosis Foundation is teaming up with drug maker Pfizer to find new treatments for patients with the most common genetic mutation of the disease.

BETHESDA, Md. — The drug-discovery division of the Cystic Fibrosis Foundation is teaming up with drug maker Pfizer to find new treatments for patients with the most common genetic mutation of the disease.

October 2, 2012

Walgreens will get a "significant" ownership stake in a specialty pharmacy that treats people with cystic fibrosis under a new deal with the Cystic Fibrosis Foundation, the two announced Tuesday.

DEERFIELD, Ill. — Walgreens will get a "significant" ownership stake in a specialty pharmacy that treats people with cystic fibrosis under a new deal with the Cystic Fibrosis Foundation, the two announced Tuesday.

January 31, 2012

The Food and Drug Administration has approved a drug made by Vertex Pharmaceuticals for treating a rare form of cystic fibrosis, the agency said Tuesday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug made by Vertex Pharmaceuticals for treating a rare form of cystic fibrosis, the agency said Tuesday.

The FDA announced the approval of Kalydeco (ivacaftor) for treating patients ages 6 years and older with CF who have a mutation called G551D in the cystic fibrosis transmembrane regulator gene.

October 20, 2011

Vertex Pharmaceuticals has filed for Food and Drug Administration approval of a drug for cystic fibrosis, the company said.

CAMBRIDGE, Mass. — Vertex Pharmaceuticals has filed for Food and Drug Administration approval of a drug for cystic fibrosis, the company said.

Vertex announced the submission to the FDA of an application for approval and priority review of Kalydeco (ivacaftor), which it said was potentially the first medicine to target the underlying cause of cystic fibrosis, namely mutations in the CFTR gene that causes defective or missing CFTR proteins that inhibit the flow of salt and water across cell membranes and lead to mucus buildup.

November 7, 2010

The Cystic Fibrosis Foundation announced on Monday that it will partner with CVS/pharmacy and Warner...

October 26, 2010

Drug maker Pharmaxis got promising results from an investigative treatment for cystic fibrosis, the company...

BALTIMORE Drug maker Pharmaxis got promising results from an investigative treatment for cystic fibrosis, the company said.

 

Pharmaxis announced results of two six-month phase-3 trials of 643 patients receiving Bronchitol (mannitol), which the company presented last week at the North American Cystic Fibrosis Conference in Baltimore.